Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023555 | 0.74 | KCNH2 (0.47) | LMNAALDH1A1CYP3A4 | |
| SCHEMBL245886 | 0.74 | KCNH2 (0.47) | LMNAALDH1A1CYP3A4 | |
| SCHEMBL243705 | 0.74 | KCNH2 (0.47) | LMNAALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL27830421 | 0.71 | KCNH2 (0.42) | TDP1L3MBTL1 | |
| SCHEMBL22481049 | 0.70 | NR1I2 (0.33) | LMNA | |
| SCHEMBL18647982 | 0.70 | NR1I2 (0.33) | LMNA | |
| SCHEMBL18893329 | 0.69 | LMNA (0.35) | PRSS1PRSS2PRSS3LMNAALDH1A1 | |
| SCHEMBL22307304 | 0.69 | KDM4E (0.38) | PRSS1PRSS2PRSS3LMNAALDH1A1 | |
| SCHEMBL23380862 | 0.68 | LMNA (0.37) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL24643904 | 0.68 | LMNA (0.37) | PRSS1PRSS2PRSS3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | PRSS1 113/4885PRSS2 307/4885PRSS3 305/4885 |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | PRSS1 113/4885PRSS2 307/4885PRSS3 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.